The US-based Cold Spring Harbor Laboratory has released two new, freely accessible protocols to help scientists understand the movement and growth of cells.

Australia's Nanostructural Analysis Network Organisation (NANO) was established four years ago to provide top-tier microscopy services for Australian scientists.

Biotechnology, genomics and molecular modelling will be boosted with grants from the Victorian Partnership for Advanced Computing (VPAC) with AUD$348,000 in funding for its round eight e-Research grants program.

Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.

Melbourne-based Epitan (ASX:APT, ADR:EPTNY, XETRA:UR9) has filed for a full international patent to protect the commercial use of the topical formulation of its melanin producing drug EPT1647 (formerly Melanotan).

pSivida has secured US$15 million (AUD$20 million) in additional funding from a New York institutional investor to assist in the development of its platform technology BioSilicon.

Melbourne's Swinburne University of Technology has developed a rapid method for the analysis of microorganisms on CD or DVD which could be used to detect bioterror agents.

Norwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system.

Sydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives.

Biomaterials company Avastra (ASX:AVS) is to abandon a clinical trial of its BioWeld Tube at Concord Repatriation and General Hospital, Sydney.

Antisense Therapeutics (ASX:ANP) has claimed successful results from animal studies targeting the growth hormone receptor with an antisense drug, designed to reduce the growth of new blood vessels that can lead to two eye diseases which are major causes of blindness.